| Catalog No. | HY260016 |
|---|
| Species reactivity | Human |
|---|
| Applications | Research Grade Biosimilar |
|---|
| Host species | Human |
|---|
| Isotype | IgG4-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Beta-type platelet-derived growth factor receptor, Beta platelet-derived growth factor receptor, CD140b, Platelet-derived growth factor receptor 1, PDGFRB, PDGF-R-beta, Platelet-derived growth factor receptor beta, CD140 antigen-like family member B, PDGFR-1, PDGFR1, PDGFR-beta, PDGFR |
|---|
| Concentration | 1mg/ml |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G, purified from cell culture supernatant. |
|---|
| Accession | P09619 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS,pH7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -166°C. |
|---|
| Alternate Names | REGN-2176,REGN-2176-3(combinationofafliberceptandricunumab),REGN2176,CAS:1569263-06-4 |
|---|
| Background | Rinucumab (REGN 2176), a monoclonal antibody, is a PDGF inhibitor. Rinucumab (REGN 2176) could be used for the study of neovascular age-related macular degeneration. |
|---|
| Note | For research use only. Not for use in clinical or therapeutic applications. |
|---|
